查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2000754

新冠疫苗市場：2026-2032年全球市場預測（依疫苗技術、劑量方案、包裝、給藥途徑、通路及最終用戶分類）

COVID-19 Vaccines Market by Vaccine Technology, Dosage Regimen, Packaging Type, Application Route, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，新冠肺炎疫苗市場價值將達到 2,601 億美元，到 2026 年將成長至 2,853 億美元，到 2032 年將達到 5,435.7 億美元，複合年成長率為 11.10%。

主要市場統計數據
基準年 2025 2601億美元
預計年份：2026年 2853億美元
預測年份：2032年 5435.7億美元
複合年成長率 (%) 11.10%

對新冠疫苗生態系統的變革進行權威解讀，重點在於科學進步、監管調整和系統韌性。

全球應對新冠疫情的行動永久重塑了整個醫療衛生生態系統中疫苗研發、公共衛生運作和商業性考量的模式。過去幾年，科學發現以前所未有的速度加速發展，推動了新型疫苗平台的湧現，同時也豐富了傳統疫苗的研發方法。同時，監管的緊迫性和嚴格的安全監測共同為適應性臨床實驗室設計和分階段核准流程樹立了新的先例。這些變化改變了製造商、支付者和醫療服務提供者評估風險、分配資源和確定投資優先順序的方式。

科學平台的多元化、供應鏈的演變以及人們的行為，是如何從根本上重塑我們用於提供 COVID-19 疫苗的策略方法的？

目前新冠疫苗接種領域正經歷多項變革性變化，這些變化持續影響所有相關人員的策略決策。傳訊RNA技術的科學成熟不僅展現了其快速應對新出現的變異株的能力，也影響未來疫苗研發平台的選擇。同時，蛋白質次單元製劑的改進，包括最佳化的佐劑系統，為需要不同安全性和反應原性特徵的人提供了更多選擇。這些並行發展豐富了產品平臺，並為生產商和採購商拓寬了策略選擇。

2025 年的關稅環境將鼓勵採購多元化、降低供應鏈風險，並促進對整個疫苗價值鏈國內製造業的投資。

2025年關稅及相關貿易措施的實施，為疫苗採購和分發的動態增添了複雜因素，影響了成本結構、籌資策略和營運計畫。關稅調整波及整個價值鏈的投入要素，包括無菌生產所需的特殊原料、一次性生產組件和包裝材料。這些調整促使採購團隊重新評估其供應商組合，探索替代籌資策略，並更重視近岸外包和區域製造夥伴關係，以降低跨境成本波動帶來的風險。

從多維細分觀點，將平台科學、管理策略、管理途徑、包裝、通路、終端用戶群和採購模式連結起來。

精細化的市場區隔架構明確了產品開發、管理策略和商業性策略應如何協調一致，以滿足多樣化的需求。就疫苗技術而言，去活化疫苗、mRNA疫苗和蛋白質次單元平台之間的差異至關重要，因為每個管道都需要不同的開發流程、製造地和低溫運輸能力。特別是蛋白質次單元疫苗，又可進一步細分為佐劑型和非佐劑型，這會影響其免疫抗原性特徵和對目標族群的適用性。就接種方案而言，加強針、單劑和雙劑接種策略的差異會影響方案設計、合規性考量，並改變採購團隊的供應預測。就給藥途徑而言，肌肉注射和鼻腔給藥的選擇決定了給藥基礎設施的要求，並可能影響特定族群的接受度。

政策框架、生產能力和分銷模式方面的區域差異如何影響了獲取和實施 COVID-19 疫苗的針對性方法？

區域趨勢持續對疫苗政策、分銷基礎設施和商業性模式產生重大影響，認知到這些差異對於制定有效策略至關重要。在美洲，大規模的公共採購項目與透過臨床和藥房管道產生的大量私人需求並存，從而形成了一種強調靈活供應合約和健全低溫運輸物流的雙重分銷模式。法規環境支持已建立的緊急使用授權機制和分階段實施的標準化上市後監測實踐，而公共衛生宣傳活動則日益側重於加強免疫接種推廣和兒童接種策略。

疫苗研發公司、契約製造和物流合作夥伴之間的策略行動：合作、擴大模組化生產能力和分銷管道多元化。

新冠疫苗領域的企業展現出廣泛的策略性舉措，涵蓋平台創新、分階段配方改進、以產能為導向的夥伴關係以及多元化的分銷管道。領先的生物製藥公司持續投資新一代疫苗平台和佐劑系統，以擴大目標族群並提升安全性和耐受性。同時，契約製造組織（CMO）和低溫運輸物流專家正在加強與疫苗研發者的合作，擴大灌裝和包裝流程的產能，並著手解決先前阻礙疫苗快速部署的瓶頸問題。

為提高疫苗利害關係人的生產柔軟性、低溫運輸透明度、監管合作和通路特定准入策略，採取切實可行的策略措施。

產業領導者可以透過將策略投資與營運實際情況和公共衛生目標結合，來提高策略投資的有效性。首先，優先發展能夠適應多種平台和劑型的靈活生產能力，可以縮短新配方的部署時間，並支援對新出現的變體做出快速反應。其次，透過數位化追蹤和整合物流夥伴關係，增強端對端低溫運輸的可視性，可以最大限度地減少廢棄物，並改善分配決策，尤其是在儲存基礎設施有限的情況下。第三，與監管機構建立合作關係，重點關注針對特定人群（例如青少年和兒童）的明確證據要求，可以簡化核准流程，並增強人們對相關項目的信心。

採用嚴謹的混合方法研究途徑，結合相關人員訪談、監管和臨床證據審查，並透過供應鏈用例進行檢驗。

本研究整合了一手和二手證據，建構了新冠疫苗現狀的全面圖像。一手資料包括對生產、物流、監管事務和公共衛生管理等環節的相關人員進行的結構化訪談，從而獲得關於營運挑戰和策略應對的第一手觀點。二手資料包括同儕審查文獻、提交給公共監管機構的文件、臨床實驗室註冊資訊和產業技術報告，以確保事實依據和論點的交叉檢驗。關於分銷和採購實踐的數據透過供應鏈流程圖和案例研究進行交叉檢驗，這些案例研究重點突出了實際營運中汲取的經驗教訓。

前瞻性的綜合分析強調，需要將科學創新、有韌性的營運結構和協調一致的措施結合起來，以確保疫苗計畫的長期成功。

隨著全球社會逐漸走出疫情初期緊急階段，新冠疫苗生態系統正邁向一個更為複雜和成熟的階段，科學創新、卓越營運和政策一致性將決定其長期成效。新型疫苗平台、不斷演進的給藥策略和多元化的供應模式的相互作用，為提升人群保護水平、同時解決公平性和可及性問題提供了多種途徑。然而，要抓住這些機遇，需要持續投資於可擴展的生產製造、更聰明的採購方式以及持續的公眾參與，以維持公眾信心和疫苗接種率。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：新冠疫苗市場：依疫苗技術分類

  • 失活
  • mRNA
  • 蛋白質次單元
    • 佐劑類型
    • 非輔助型

第9章：新冠疫苗市場：依劑量方案分類

  • 加強劑量
  • 1. 接種疫苗
  • 兩劑疫苗

第10章：新冠疫苗市場：依包裝類型分類

  • 預填充式注射器
  • 管瓶

第11章：新冠疫苗市場：依給藥途徑分類

  • 肌肉內部
  • 鼻內

第12章：新冠疫苗市場：依通路分類

  • 診所
  • 醫院
  • 藥局

第13章：新冠肺炎疫苗市場：依最終用戶分類

  • 青少年
  • 成人
  • 兒童

第14章：新冠肺炎疫苗市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：新冠疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：新冠肺炎疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國新冠疫苗市場

第18章：中國新冠疫苗市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AIVITA Biomedical Inc.
  • AstraZeneca Plc
  • Baseimmune Ltd.
  • Bharat BIoTech International Ltd.
  • Biological E. Ltd.
  • CanSino Biologics Inc.
  • Centivax Inc.
  • Codagenix Inc.
  • CureVac SE
  • Dr. Reddy's Laboratories Ltd.
  • Emergex Vaccines Holding Ltd.
  • Etherna Immunotherapies Nv
  • Gennova Biopharmaceuticals Ltd.
  • GlaxoSmithKline plc.
  • HDT Bio, Inc.
  • Meissa Vaccines, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax Inc.
  • Osivax SAS
  • Pfizer Inc.
  • Providence Therapeutics Inc.
  • SANOFI
  • Serum Institute of India Pvt. Ltd.
  • Sinovac BIoTech Ltd.
  • Vaccitech PLC
  • Zydus Lifesciences Ltd.
Product Code: MRR-02026C4C976F

The COVID-19 Vaccines Market was valued at USD 260.10 billion in 2025 and is projected to grow to USD 285.30 billion in 2026, with a CAGR of 11.10%, reaching USD 543.57 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 260.10 billion
Estimated Year [2026] USD 285.30 billion
Forecast Year [2032] USD 543.57 billion
CAGR (%) 11.10%

An authoritative orientation to the transformed COVID-19 vaccine ecosystem highlighting scientific acceleration, regulatory adaptation, and system-level resilience

The global response to COVID-19 has permanently reshaped vaccine development paradigms, public health operations, and commercial considerations across the healthcare ecosystem. Over the past years, scientific discovery accelerated at an unprecedented pace, catalyzing novel vaccine platforms alongside traditional approaches. Simultaneously, the interplay between regulatory urgency and rigorous safety oversight created new precedents for adaptive clinical trial design and rolling submission pathways. These shifts have changed how manufacturers, payers, and providers evaluate risk, allocate resources, and prioritize investments.

Against this backdrop, supply chain resilience emerged as a strategic priority, intersecting cold chain logistics, raw material sourcing, and contract manufacturing capacity. Public health demand patterns evolved as populations experienced heterogeneous rates of vaccine uptake, booster acceptance, and variant-driven needs, prompting programmatic adjustments. Market entrants and incumbents alike must now operate within a landscape where scientific innovation coexists with complex distribution requirements and heightened public scrutiny. Consequently, the industry's next phase emphasizes scalable manufacturing, transparent communication strategies, and policy alignment to sustain immunization programs and maintain public trust.

How scientific platform diversification, supply chain evolution, and public behavior are fundamentally reshaping strategic approaches to COVID-19 vaccination delivery

The landscape of COVID-19 vaccination is defined by several transformative shifts that continue to influence strategic decision-making across stakeholders. Scientific maturation of messenger RNA technology has not only demonstrated rapid response capability against emerging variants but has also influenced platform selection for future vaccine development. Concurrently, improvements in protein subunit formulations, including optimized adjuvant systems, have expanded options for populations that require different safety and reactogenicity profiles. These parallel developments have created a more diversified product pipeline and widened strategic choices for manufacturers and purchasers.

Operationally, distribution networks have adapted to balance high-throughput mass vaccination campaigns with targeted, routine delivery through clinical and pharmacy channels. Policy frameworks evolved to accommodate pandemic-era emergency measures while progressively integrating lessons into standard regulatory processes. Supply chain orchestration improved through strategic partnerships with contract manufacturers and cold chain logistics providers, yet vulnerabilities remain in specialized inputs and capacity bottlenecks. Moreover, public sentiment and behavioral dynamics around booster acceptance and pediatric immunization continue to shape demand signals, necessitating ongoing engagement strategies that combine transparent evidence communication with tailored access programs.

The 2025 tariff environment catalyzing sourcing diversification, supply chain de-risking, and domestic manufacturing investment across the vaccine value chain

The imposition of tariffs and related trade measures in 2025 has added a complex layer to vaccine procurement and distribution dynamics, influencing cost profiles, sourcing strategies, and operational planning. Tariff changes affected inputs across the value chain, including specialized raw materials, single-use manufacturing components, and packaging supplies that are critical to sterile production. These adjustments prompted procurement teams to reassess supplier portfolios, seek alternative sourcing strategies, and increase emphasis on nearshoring or regional manufacturing partnerships to reduce exposure to cross-border cost volatility.

In response to heightened tariff risk, supply chain managers intensified supplier qualification processes and pursued contractual protections to insulate production continuity. Cold chain logistics providers and contract manufacturers recalibrated pricing models to reflect the incremental costs and administrative burdens associated with cross-border movements. At the same time, health systems and public purchasers evaluated procurement models with more pronounced scrutiny on total landed cost, lead times, and supply guarantees. The tariff landscape also incentivized investment in domestic fill-and-finish capacity and partnerships that prioritized geographic diversification, thereby improving strategic resilience but requiring capital allocation and longer-term planning.

A multi-dimensional segmentation perspective connecting platform science, dosage strategy, delivery route, packaging, distribution channels, end-user cohorts, and procurement models

A granular segmentation framework clarifies where product development, delivery strategies, and commercial approaches must be tailored to meet heterogeneous needs. Based on Vaccine Technology, distinctions among Inactivated, mRNA, and Protein Subunit platforms matter because each pathway demands different development timelines, manufacturing footprints, and cold chain capabilities; notably, Protein Subunit vaccines are further delineated between Adjuvanted and Non Adjuvanted formulations, which influence immunogenicity profiles and target population suitability. Based on Dosage Regimen, differences across Booster Dose, Single Dose, and Two Dose strategies drive programmatic design, influence adherence considerations, and alter supply forecasting horizons for procurement teams. Based on Application Route, the choice between Intramuscular and Intranasal delivery defines administration infrastructure needs and can affect acceptance rates among specific populations.

Further segmentation based on Packaging Type-Prefilled Syringe versus Vial-has operational implications for wastage rates, administration speed in mass clinics, and cold chain volume planning. Distribution Channel segmentation spanning Clinic, Hospital, and Pharmacy underscores the necessity of channel-specific engagement models and reimbursement considerations. End User segmentation across Adolescent, Adult, and Child cohorts requires tailored clinical evidence packages, safety communications, and dosing strategies to achieve uptake targets. Finally, Procurement Model segmentation between Government Procurement and Private Purchase shapes pricing negotiations, contracting structures, and access pathways, thereby influencing how manufacturers structure commercial offers and manage channel partnerships. Together, these segmentation lenses enable stakeholders to match product attributes to operational realities and population needs.

How differentiated regional policy frameworks, manufacturing capacity, and distribution models are shaping targeted approaches to COVID-19 vaccine access and program execution

Regional dynamics continue to exert significant influence on vaccine policy, distribution infrastructure, and commercial approaches, and recognizing these differences is essential to effective strategy formation. In the Americas, large public procurement programs coexist with substantial private demand through clinical and pharmacy channels, leading to a dual-track distribution model that emphasizes flexible supply agreements and robust cold chain logistics. The regulatory environment favors established emergency authorization mechanisms and progressive alignment toward standardized post-market surveillance practices, while public health campaigns increasingly focus on booster outreach and pediatric dosing strategies.

In Europe, Middle East & Africa, the landscape is more heterogeneous, with advanced regulatory systems in some markets and capacity constraints in others. This diversity drives strategies that combine regional manufacturing hubs, targeted deployment programs, and tailored financing mechanisms to improve access. Public-private partnerships and international procurement consortia play a pivotal role in addressing inequities and logistical gaps. In Asia-Pacific, rapid manufacturing scale-up capabilities, a growing contract manufacturing ecosystem, and diverse regulatory timelines create both opportunities and complexity for market entrants. Regional players emphasize supply reliability, competitive pricing, and the ability to support large-scale immunization campaigns, while also navigating evolving local regulatory expectations and distribution modalities. Across all regions, collaboration between policymakers, manufacturers, and service providers remains a critical enabler of effective vaccine program implementation.

Strategic behaviors among vaccine developers, contract manufacturers, and logistics partners revealing collaboration, modular capacity expansion, and channel diversification

Companies operating in the COVID-19 vaccine space demonstrate a range of strategic postures, from platform innovation and incremental formulation improvements to capacity-focused partnerships and diversified commercial channels. Leading biopharmaceutical firms have continued to invest in next-generation vaccine platforms and adjuvant systems to widen their addressable populations and improve safety and tolerability profiles. At the same time, contract manufacturing organizations and cold chain logistics specialists have strengthened alliances with vaccine developers to expand fill-and-finish throughput and reduce bottlenecks that previously constrained rapid deployment.

Strategic collaboration has become a dominant theme, with alliances spanning clinical research universities, biotech innovators, and global distribution partners to accelerate candidate progression while managing cost and risk. Some companies have prioritized modular manufacturing designs that facilitate rapid switching between vaccine types, whereas others have invested in regional production footprints to mitigate trade-related disruptions. Commercial strategies increasingly blend direct government contracting with pharmacy and clinic channel engagement, supported by targeted educational campaigns to address hesitancy. Overall, the competitive dynamic rewards organizations that can combine scientific agility with operational scalability and credible, transparent stakeholder communication.

Practical strategic moves for vaccine stakeholders to enhance manufacturing flexibility, cold chain visibility, regulatory engagement, and channel-specific access approaches

Industry leaders can accelerate impact by aligning strategic investments with operational realities and public health objectives. First, prioritizing flexible manufacturing capacity-capable of handling multiple platforms and dose configurations-reduces time-to-deployment for novel formulations and supports rapid response to emergent variants. Second, strengthening end-to-end cold chain visibility through digital tracking and integrated logistics partnerships minimizes wastage and improves allocation decisions, particularly in contexts with constrained storage infrastructure. Third, cultivating regulatory engagement that focuses on clear evidence requirements for specific populations, such as adolescents and children, streamlines approval pathways and bolsters program confidence.

In parallel, adopting differentiated channel strategies that recognize the distinct roles of clinics, hospitals, and pharmacies ensures broader access while addressing local administration preferences. Investment in tailored risk communication and community engagement programs can improve booster acceptance and sustain immunization momentum. Finally, exploring procurement structures that combine long-term supply commitments with options for private purchase supports both public health objectives and commercial sustainability. Together, these actions enhance resilience, support equitable access, and create a more predictable operating environment for vaccine stakeholders.

A rigorous mixed-methods research approach integrating stakeholder interviews, regulatory and clinical evidence review, and supply chain case study triangulation

This research synthesizes primary and secondary evidence to construct a comprehensive view of the COVID-19 vaccine landscape. Primary inputs included structured interviews with stakeholders across manufacturing, logistics, regulatory affairs, and public health administration, providing firsthand perspectives on operational challenges and strategic responses. Secondary inputs encompassed peer-reviewed literature, public regulatory filings, clinical trial registries, and industry technical reports to ensure factual grounding and cross-validation of claims. Data on distribution and procurement practices were triangulated through supply chain process mapping and case studies that highlight real-world implementation lessons.

Analytical methods combined qualitative thematic analysis with comparative scenario assessment to surface risks and identify resilience strategies. The methodology emphasized transparency in sourcing and reproducibility in approach, with clear documentation of interview protocols, inclusion criteria for secondary sources, and the analytical frameworks used to synthesize findings. Where appropriate, the research incorporated sensitivity checks to evaluate how changes in trade policy, variant emergence, or public acceptance could alter operational priorities. This mixed-method approach ensures that insights reflect both empirical evidence and pragmatic perspectives from practitioners.

A forward-looking synthesis that underscores the necessity of aligning scientific innovation, resilient operations, and collaborative policy to secure long-term vaccine program success

As the global community moves beyond the initial pandemic emergency phase, the COVID-19 vaccine ecosystem is settling into a more complex, mature era where scientific innovation, operational excellence, and policy coherence determine long-term outcomes. The interplay of novel platforms, evolving dosage strategies, and diversified delivery models offers multiple pathways to improve population protection while addressing equity and access concerns. However, realizing these opportunities requires continued investment in scalable manufacturing, smarter procurement practices, and sustained public engagement to maintain confidence and uptake.

Looking ahead, the capacity to integrate scientific advances with resilient supply chains and adaptive regulatory strategies will define organizational success. Stakeholders that proactively manage tariff and trade risks, invest in modular production capabilities, and tailor approaches to regional realities will be better positioned to deliver reliable access to vaccines. Ultimately, the sector's progress will depend on collaborative problem-solving across public and private actors to align incentives, share capacity, and prioritize interventions that maximize public health benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. COVID-19 Vaccines Market, by Vaccine Technology

  • 8.1. Inactivated
  • 8.2. mRNA
  • 8.3. Protein Subunit
    • 8.3.1. Adjuvanted
    • 8.3.2. Non Adjuvanted

9. COVID-19 Vaccines Market, by Dosage Regimen

  • 9.1. Booster Dose
  • 9.2. Single Dose
  • 9.3. Two Dose

10. COVID-19 Vaccines Market, by Packaging Type

  • 10.1. Prefilled Syringe
  • 10.2. Vial

11. COVID-19 Vaccines Market, by Application Route

  • 11.1. Intramuscular
  • 11.2. Intranasal

12. COVID-19 Vaccines Market, by Distribution Channel

  • 12.1. Clinic
  • 12.2. Hospital
  • 12.3. Pharmacy

13. COVID-19 Vaccines Market, by End User

  • 13.1. Adolescent
  • 13.2. Adult
  • 13.3. Child

14. COVID-19 Vaccines Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. COVID-19 Vaccines Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. COVID-19 Vaccines Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States COVID-19 Vaccines Market

18. China COVID-19 Vaccines Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AIVITA Biomedical Inc.
  • 19.6. AstraZeneca Plc
  • 19.7. Baseimmune Ltd.
  • 19.8. Bharat Biotech International Ltd.
  • 19.9. Biological E. Ltd.
  • 19.10. CanSino Biologics Inc.
  • 19.11. Centivax Inc.
  • 19.12. Codagenix Inc.
  • 19.13. CureVac SE
  • 19.14. Dr. Reddy's Laboratories Ltd.
  • 19.15. Emergex Vaccines Holding Ltd.
  • 19.16. Etherna Immunotherapies Nv
  • 19.17. Gennova Biopharmaceuticals Ltd.
  • 19.18. GlaxoSmithKline plc.
  • 19.19. HDT Bio, Inc.
  • 19.20. Meissa Vaccines, Inc.
  • 19.21. Merck & Co., Inc.
  • 19.22. Moderna, Inc.
  • 19.23. Novavax Inc.
  • 19.24. Osivax SAS
  • 19.25. Pfizer Inc.
  • 19.26. Providence Therapeutics Inc.
  • 19.27. SANOFI
  • 19.28. Serum Institute of India Pvt. Ltd.
  • 19.29. Sinovac Biotech Ltd.
  • 19.30. Vaccitech PLC
  • 19.31. Zydus Lifesciences Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COVID-19 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COVID-19 VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COVID-19 VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COVID-19 VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COVID-19 VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL COVID-19 VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES COVID-19 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA COVID-19 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COVID-19 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COVID-19 VACCINES MARKET SIZE, BY MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COVID-19 VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COVID-19 VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADJUVANTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADJUVANTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADJUVANTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COVID-19 VACCINES MARKET SIZE, BY NON ADJUVANTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COVID-19 VACCINES MARKET SIZE, BY NON ADJUVANTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COVID-19 VACCINES MARKET SIZE, BY NON ADJUVANTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COVID-19 VACCINES MARKET SIZE, BY BOOSTER DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COVID-19 VACCINES MARKET SIZE, BY BOOSTER DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COVID-19 VACCINES MARKET SIZE, BY BOOSTER DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COVID-19 VACCINES MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COVID-19 VACCINES MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COVID-19 VACCINES MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COVID-19 VACCINES MARKET SIZE, BY TWO DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COVID-19 VACCINES MARKET SIZE, BY TWO DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COVID-19 VACCINES MARKET SIZE, BY TWO DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COVID-19 VACCINES MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COVID-19 VACCINES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COVID-19 VACCINES MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COVID-19 VACCINES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADOLESCENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADOLESCENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CHILD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CHILD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CHILD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COVID-19 VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS COVID-19 VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL COVID-19 VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. GCC COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GCC COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. GCC COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 140. GCC COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 141. GCC COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. GCC COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 143. GCC COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. GCC COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. G7 COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. G7 COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. G7 COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 164. G7 COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 165. G7 COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. G7 COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 167. G7 COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. G7 COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. NATO COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. NATO COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. NATO COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 172. NATO COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 173. NATO COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. NATO COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 175. NATO COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. NATO COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES COVID-19 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA COVID-19 VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA COVID-19 VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA COVID-19 VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA COVID-19 VACCINES MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA COVID-19 VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA COVID-19 VACCINES MARKET SIZE, BY APPLICATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA COVID-19 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA COVID-19 VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)